Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Large B-Cell Transformation in Hodgkin Lymphoma

Blood; 2016 Apr 21; Kenderian, Habermann, et al

The risk of large B-cell transformation is lower in people with new untreated nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) than it is in other low-grade lymphomas, according to an analysis involving 222 individuals.

Using the Mayo Clinic Lymphoma Database, investigators identified adults with NLPHL, and followed them for a median of 16 years. Participants averaged 40 years of age when diagnosed, and two-thirds were males. Among the results:

• The lymphomas of 17 patients transformed to diffuse large B-cell lymphoma.

• Median time to transformation was ~3 years.

• Transformation rate was 0.74 per 100 patient-years.

• Those who used chemotherapy previously had a significantly higher risk of transformation, as did those whose spleen was involved.

• 5-year overall survival was ~76% in those who lymphomas transformed.

• Transformation did not negatively impact survival when compared with those who did not experience transformation.

Citation: Kenderian S, Habermann T, Macon W, et al. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood. 2016;127(16):1960-1966. doi:http://dx.doi.org/10.1182/blood-2015-08-665505.